Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and...
NGM Bio’s three-pronged corporate strategy includes the following components: Focus internal clinical development efforts on solid tumor oncology portfolio Generate next-generation biologics through prolific in-house discovery engine Seek partners for other NGM-discovered p...
--NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical in vivo and in vitro studies-- --Immunoglobulin-like transcript 3 (ILT3) is a highly s...
NGM707 was generally well tolerated to the highest dose evaluated (1800 mg) in the monotherapy escalation; maximum tolerated dose was not reached Linear pharmacokinetics (PK) was observed at doses ≥200 mg, and analysis of peripheral immune cells demonstrated dose-dependent receptor occ...
Poster presentation to showcase initial data from the Phase 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in patients with advanced solid tumors ILT2 and ILT4, both upregulated in certain tumor type...
--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive cancer cells-- --Oral presentation from the lab...
NGM Biopharmaceuticals press release ( NASDAQ: NGM ): Q3 GAAP EPS of -$0.59 beats by $0.02 . Revenue of $7.91M (-57.4% Y/Y) beats by $0.85M . NGM Bio reported a net loss of $47.3 million for the quarter ended September 30, 2022, compared to a net loss...
--Announced that the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham-- ...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the presentation of findings from post-hoc analyses of...
How Do Penny Stock Traders Follow The Money? One of the most exciting things about trading penny stocks is making quick money. But finding companies to add to your watch list can be easier said than done. There are plenty of trading strategies to use to do so, and one of the more po...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...